Empresas Andrómaco

Empresas Andrómaco is a leading Chilean pharmaceutical company that specializes in the development, production, and marketing of a wide range of healthcare products. With a strong heritage dating back to 1923, the company has established itself as a dominant player in the Latin American market, particularly in therapeutic areas such as dermatology, pain management, and women's health. In 2013, the company was acquired by the German pharmaceutical group Grünenthal for approximately $360 million, integrating its extensive regional distribution network and manufacturing capabilities into Grünenthal's global operations. The company operates state-of-the-art manufacturing facilities in Santiago, producing both branded and generic medications that serve millions of patients across the Andean region and Central America. As a subsidiary of Grünenthal, Empresas Andrómaco continues to leverage its local expertise and brand equity to drive growth in the pharmaceutical sector.